Active, not recruitingPhase 3NCT05477524
An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)
Studying Lyme disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- VLA15(biological)
- Enrollment
- 12547 target
- Eligibility
- 5 years · All sexes
- Timeline
- 2022 – 2025
Study locations (30)
- Care Access - Essex, Essex, Connecticut, United States
- Care Access Mobile Site, New London, Connecticut, United States
- Stamford Health Medical Group, Stamford, Connecticut, United States
- Stamford Hospital, Stamford, Connecticut, United States
- Northern Light Eastern Maine Medical Center, Bangor, Maine, United States
- Care Access - Farmington, Farmington, Maine, United States
- Pen Bay Medical Center, Rockport, Maine, United States
- Johns Hopkins, Baltimore, Maryland, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- Johns Hopkins Rockland Physician Practice and Research Group, Lutherville, Maryland, United States
- Sumit Bhutani MD LLC, Westminster, Maryland, United States
- Woodholme Gastroenterology Associates, Westminster, Maryland, United States
- Pediatric Associates of Fall River, Fall River, Massachusetts, United States
- Care Access - Lakeville, Lakeville, Massachusetts, United States
- Care Access - Melrose, Melrose, Massachusetts, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Valneva Austria GmbH
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05477524 on ClinicalTrials.govOther trials for Lyme disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06785402Ceftriaxone for Post-Treatment Lyme DiseaseHackensack Meridian Health
- RECRUITINGPHASE3NCT07226882A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy AdultsPfizer
- RECRUITINGPHASE4NCT06451913Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis))Biocodex
- RECRUITINGNANCT06915324Transcranial Direct Current Stimulation for Post Treatment Lyme DiseaseColumbia University
- RECRUITINGEARLY PHASE1NCT06611111Ceftriaxone Pulse Dose for Post-Treatment Lyme DiseaseState University of New York - Upstate Medical University
- ACTIVE NOT RECRUITINGNCT06835075Clinicaly Manifested Reinfections with Borrelia Burgdorferi Sensu LatoUniversity Medical Centre Ljubljana
- ACTIVE NOT RECRUITINGNCT06731179A Prospective Study to Evaluate the Role of T-Cell Dysfunction in Patients Who Present Symptoms Associated With Long COVID, Lyme Disease and Myalic Encephalomyelitis / Chronic Fatigue Syndrome Using the Vira Immune Fluorospot T Cell AssayViraxBio Labs
- RECRUITINGPHASE1, PHASE2NCT06511050Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue SyndromeIcahn School of Medicine at Mount Sinai